- Xenon Pharmaceuticals Inc Corporate Update TranscriptNov 27, 2023
- Q3 2023 Xenon Pharmaceuticals Inc Earnings Call TranscriptNov 08, 2023$32.15 (+1.13%)Earnings
- Xenon Pharmaceuticals Inc XEN1101 and the Major Depressive Disorder (MDD) Landscape: A Discussion with KOLs TranscriptSep 19, 2023
- Q2 2023 Xenon Pharmaceuticals Inc Earnings Call TranscriptAug 09, 2023$35.45 (+0.28%)Earnings
- Xenon Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Xenon Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Xenon Pharmaceuticals Inc Annual Shareholders Meeting TranscriptJun 01, 2023
- Xenon Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 16, 2023
- Xenon Pharmaceuticals Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Q1 2023 Xenon Pharmaceuticals Inc Earnings Call TranscriptMay 09, 2023$43.54 (+2.45%)Earnings
- Xenon Pharmaceuticals Inc at Bloom Burton & Co Healthcare Investor Conference TranscriptApr 25, 2023
- Xenon Pharmaceuticals Inc at Stifel CNS Days (Virtual) TranscriptMar 28, 2023
- Q4 2022 Xenon Pharmaceuticals Inc Earnings Call TranscriptMar 01, 2023$40.35 (+2.26%)Earnings
- Xenon Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Xenon Pharmaceuticals Inc at Bank of America Biotech SMID Cap Conference TranscriptDec 07, 2022
- Q3 2022 Xenon Pharmaceuticals Inc Earnings Call TranscriptNov 08, 2022$35.4 (+1.81%)Earnings
- Q2 2022 Xenon Pharmaceuticals Inc Earnings Call TranscriptAug 09, 2022$39.35 (-0.76%)Earnings
- Xenon Pharmaceuticals Inc Annual Shareholders Meeting TranscriptJun 01, 2022
- Q1 2022 Xenon Pharmaceuticals Inc Earnings Call TranscriptMay 10, 2022$28.57 (+12.30%)Earnings
- Xenon Pharmaceuticals Inc at Bloom Burton & Co. Healthcare Investor Conference TranscriptMay 03, 2022
- Xenon Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 11, 2022
- Xenon Pharmaceuticals Inc at Stifel CNS Days (Virtual) TranscriptMar 29, 2022
- Q4 2021 Xenon Pharmaceuticals Inc Earnings Call TranscriptMar 01, 2022$31.76 (+0.19%)Earnings
- Xenon Pharmaceuticals Inc X-TOLE Results Update AES 2021 Call TranscriptDec 03, 2021
- Q3 2021 Xenon Pharmaceuticals Inc Earnings Call TranscriptNov 10, 2021$33.79 (-4.14%)Earnings
- Xenon Pharmaceuticals Inc Positive Topline Results from Phase 2b 'X-TOLE' Clinical Trial of XEN1101 Call TranscriptOct 04, 2021
- Q2 2021 Xenon Pharmaceuticals Inc Earnings Call TranscriptAug 11, 2021$18.68 (+11.19%)Earnings
- Xenon Pharmaceuticals Inc at William Blair Biotech Focus Conference (Virtual) TranscriptJul 15, 2021
- Xenon Pharmaceuticals Inc Discussion of XEN1101 and the Focal Epilepsy Landscape TranscriptJul 12, 2021
- Q1 2021 Xenon Pharmaceuticals Inc Earnings Call TranscriptMay 11, 2021$17.93 (-1.27%)Earnings
- Full Year 2020 Xenon Pharmaceuticals Inc Earnings Call TranscriptMar 01, 2021$17.92 (-4.07%)Earnings
- Q3 2020 Xenon Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2020$11.85 (+5.52%)Earnings
- Q2 2020 Xenon Pharmaceuticals Inc Earnings Call TranscriptAug 06, 2020$11.3 (-1.22%)Earnings
- Xenon Pharmaceuticals Inc Annual Shareholders Meeting TranscriptJun 01, 2020
- Q1 2020 Xenon Pharmaceuticals Inc Earnings Call TranscriptMay 21, 2020$13.87 (-2.94%)Earnings
- Q4 2019 Xenon Pharmaceuticals Inc Earnings Call TranscriptMar 09, 2020$12.12 (-14.53%)Earnings
- Xenon Pharmaceuticals Inc. - Special Call TranscriptDec 02, 2019
- Q3 2019 Xenon Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2019$9.15 (+1.44%)Earnings
- Q2 2019 Xenon Pharmaceuticals Inc Earnings Call TranscriptAug 06, 2019$9.18 (+2.80%)Earnings
- Q1 2019 Xenon Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2019$9.5 (-2.46%)Earnings
- Full Year 2018 Xenon Pharmaceuticals Inc Earnings Call TranscriptMar 06, 2019$8.78 (+1.27%)Earnings
Xenon Pharmaceuticals Inc at Bloom Burton & Co. Healthcare Investor Conference Transcript
Xenon Pharmaceuticals, presented by Ian Mortimer, President and CEO.
Great, thanks for the introduction. And thanks to Bloom Burton for hosting us today. So if we look back over the last 12 months when we gave this presentation virtually a year ago, a huge massive transformation at Xenon. We had really compelling data in our lead program XEN1101 last fall, that allowed us to raise large amounts of capital. And now we're in a position to start our Phase 3 program later this year.
So I'm going to focus, although we have a pipeline of programs, I'm going to focus the presentation today on our XEN1101 program.
We are a public company listed on NASDAQ, so I will make some forward-looking statements, and I encourage you to look at our risk factors filed with the SEC and on SEDAR. So for those of you that are new to the Xenon story, we're a neurology-focused company, deep expertise in epilepsy, and a growing interest in depression.
And we actually had an
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)